Trending...
- Cal State LA continues remarkable climb in U.S. News & World Report rankings
- Hip Hop Recording Artist Dukk Drops New September Music Release
- For National Small Business Week: Some very Essential Advertising Math Every Business Needs to Know
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) securities between July 8, 2020 and May 13, 2021, inclusive (the "Class Period"). CorMedix investors have until September 20, 2021 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
In July 2020, CorMedix filed its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for DefenCath, an antibacterial and antifungal solution, as a catheter lock solution with an initial indication for use of preventing certain catheter-related bloodstream infections.
On March 1, 2021, CorMedix announced the NDA would not be approved "in its present form" due to "concerns at the third-party manufacturing facility." Moreover, the FDA "is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume within specifications."
More on The Californer
On this news, CorMedix's stock price fell $5.98 per share, or 39.87%, to close at $9.02 per share on March 1, 2021.
Then, on April 14, 2021, CorMedix announced it would have to take additional steps to meet the FDA's requirements for DefenCath's manufacturing process, including "[a]ddressing FDA's concerns regarding the qualification of the filling operation [that] may necessitate adjustments in the process and generation of additional data on operating parameters for manufacture of DefenCath."
On this news, CorMedix's stock price fell $1.44 per share, or 15.37%, to close at $7.93 per share on April 14, 2021.
Then, on May 13, 2021, CorMedix announced that "[b]ased on our analyses, we have concluded that additional process qualification will be needed with subsequent validation to address the deficiencies identified by FDA." Among other things, the Company was required "to generate sufficient data to demonstrate that [the filling] process is a controlled process and is consistent with the agency's requirements for good manufacturing practice."
On this news, CorMedix's stock price fell $1.51 per share, or 19.97%, to close at $6.05 per share on May 14, 2021.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors the following: (1) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (2) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for CRBSIs in its present form; (3) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The Californer
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased CorMedix securities during the Class Period, you may move the Court no later than September 20, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased CorMedix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you are a shareholder who suffered a loss, click here to participate.
In July 2020, CorMedix filed its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for DefenCath, an antibacterial and antifungal solution, as a catheter lock solution with an initial indication for use of preventing certain catheter-related bloodstream infections.
On March 1, 2021, CorMedix announced the NDA would not be approved "in its present form" due to "concerns at the third-party manufacturing facility." Moreover, the FDA "is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume within specifications."
More on The Californer
- California: Governor Newsom Issues Proclamation Declaring Latino Heritage Month 2021
- California: Newsom Administration Awards Nearly $138 Million in Fire Prevention Grants to Build Resilience in Local Communities
- California: Governor Newsom Announces Appointments 9.15.21
- Kobe Bryant Inspired KB24 NFT Art on Course to Raise Millions for Foundation
- Welcoming President Biden to Long Beach
On this news, CorMedix's stock price fell $5.98 per share, or 39.87%, to close at $9.02 per share on March 1, 2021.
Then, on April 14, 2021, CorMedix announced it would have to take additional steps to meet the FDA's requirements for DefenCath's manufacturing process, including "[a]ddressing FDA's concerns regarding the qualification of the filling operation [that] may necessitate adjustments in the process and generation of additional data on operating parameters for manufacture of DefenCath."
On this news, CorMedix's stock price fell $1.44 per share, or 15.37%, to close at $7.93 per share on April 14, 2021.
Then, on May 13, 2021, CorMedix announced that "[b]ased on our analyses, we have concluded that additional process qualification will be needed with subsequent validation to address the deficiencies identified by FDA." Among other things, the Company was required "to generate sufficient data to demonstrate that [the filling] process is a controlled process and is consistent with the agency's requirements for good manufacturing practice."
On this news, CorMedix's stock price fell $1.51 per share, or 19.97%, to close at $6.05 per share on May 14, 2021.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors the following: (1) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (2) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for CRBSIs in its present form; (3) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The Californer
- California: Governor Newsom Highlights New In-Person Student Rates, Nation-Leading School Safety & Prevention Efforts
- San Jose: Media Advisory: Ribbon-Cutting Ceremony at Solari Park to Commemorate New Playground
- San Jose: Media Advisory: Viva CalleSJ is Back to Activate the Streets and Create the City's Largest Park
- MG Facility Services Awarded $30 Million, Multi-Year Contract With The U.S. Environmental Protection Agency
- Michelle Danner's "The Runner" to screen at Catalina Film Festival
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased CorMedix securities during the Class Period, you may move the Court no later than September 20, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased CorMedix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The Californer
- For the 6th Time, Zippy Shell, Inc. Appears on the Inc. 5000, Ranking No. 1149 With Three-Year Revenue Growth of 423 Percent
- Global Sandalwood Oil Market to Reach $149.1 Million by 2026
- Creating Art During The Pandemic Artist Cynthia Warden Launches Original Art Series Featuring Events Of 2020 and Beyond
- STEMconnector, Million Women Mentors and Olay: Face the STEM Gap Role Model Event September 15, 2021
- Latino Author Wants Better Representation of Latino and Hispanic Creatives Beyond Hispanic Heritage Month
- What Does Post-Traumatic Thriving Look Like?
- EdTech Startup Builds on Early Traction in Remote Proctoring with New Crowdfunding Round
- Shero Comics' Rayven Choi Graphic Novel Series Will Take Final Bow on National Comic Book Day
- What are the Safety Measures to fly with Copa Airlines
- Speck Unveils Line of MagSafe Compatible Cases and Accessories for all New Apple Devices
- ELEVATE (ELEctric Vehicle AdapTEr) adds Demand Response to any Electric Vehicle charger
- SCHURTER continues revamp of EMC filters with flagship FMBD EP for 3-phase power systems and machine
- BCVWD Named One of the Best Places to Work in the Country
- New Classical Music Show Plays Only the Classical Music Great's Symphonies
- The 5-Star Reviews Keep Coming for "Shadows in Light"
- Voices of Silicon Valley conductor is selected Grammys member
- TOArts' AccessArts Program announces $50,000 available to support arts education in Ventura
- With Market Size Valued at $618.7 Billion by 2026, it`s a Healthy Outlook for the Global Photovoltaics Market
- Exclusionary Vehicle Coverage from autopom! Is As Close To New Car Coverage As You Can Get
- Kairos Strategy Group Announces Commitment to Global Efforts Advocating for Cybersecurity Best Practices during Cybersecurity Awareness Month